The Goldman Sachs Group Initiates Coverage on Silence Therapeutics (NASDAQ:SLN)

The Goldman Sachs Group initiated coverage on shares of Silence Therapeutics (NASDAQ:SLN) in a research note published on Tuesday morning, Marketbeat Ratings reports. The firm issued a sell rating and a $6.00 price objective on the stock.

Several other research analysts have also commented on SLN. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. HC Wainwright restated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Wednesday, January 29th. Chardan Capital restated a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a report on Tuesday, December 10th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Silence Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $45.00.

Silence Therapeutics Price Performance

Shares of SLN stock opened at $4.50 on Tuesday. Silence Therapeutics has a 1-year low of $4.06 and a 1-year high of $27.72. The firm’s 50-day simple moving average is $6.10 and its 200-day simple moving average is $12.84. The firm has a market cap of $134.69 million, a P/E ratio of -2.87 and a beta of 1.05.

Institutional Trading of Silence Therapeutics

A number of hedge funds have recently made changes to their positions in SLN. Eventide Asset Management LLC acquired a new stake in shares of Silence Therapeutics during the third quarter worth approximately $11,635,000. Point72 Asset Management L.P. grew its position in shares of Silence Therapeutics by 219.3% during the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock worth $8,505,000 after buying an additional 321,300 shares in the last quarter. Marshall Wace LLP grew its position in shares of Silence Therapeutics by 190.3% during the fourth quarter. Marshall Wace LLP now owns 488,889 shares of the company’s stock worth $3,364,000 after buying an additional 320,472 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Silence Therapeutics by 32.8% during the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock worth $19,798,000 after buying an additional 268,250 shares in the last quarter. Finally, Parkman Healthcare Partners LLC grew its position in shares of Silence Therapeutics by 71.8% during the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock worth $9,051,000 after buying an additional 208,029 shares in the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.